JP2020528758A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528758A5
JP2020528758A5 JP2020505231A JP2020505231A JP2020528758A5 JP 2020528758 A5 JP2020528758 A5 JP 2020528758A5 JP 2020505231 A JP2020505231 A JP 2020505231A JP 2020505231 A JP2020505231 A JP 2020505231A JP 2020528758 A5 JP2020528758 A5 JP 2020528758A5
Authority
JP
Japan
Prior art keywords
domain
polypeptide chain
functional
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505231A
Other languages
English (en)
Japanese (ja)
Other versions
JP7297734B2 (ja
JP2020528758A (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/069357 external-priority patent/WO2019024979A1/en
Application filed filed Critical
Publication of JP2020528758A publication Critical patent/JP2020528758A/ja
Publication of JP2020528758A5 publication Critical patent/JP2020528758A5/ja
Priority to JP2023097920A priority Critical patent/JP2023123588A/ja
Application granted granted Critical
Publication of JP7297734B2 publication Critical patent/JP7297734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505231A 2017-07-31 2018-07-30 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体 Active JP7297734B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023097920A JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/069357 2017-07-31
PCT/EP2017/069357 WO2019024979A1 (en) 2017-07-31 2017-07-31 FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
PCT/EP2018/070640 WO2019025391A1 (en) 2017-07-31 2018-07-30 ANTIBODIES HAVING FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN A VARIABLE DOMAIN AND A CONSTANT DOMAIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097920A Division JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Publications (3)

Publication Number Publication Date
JP2020528758A JP2020528758A (ja) 2020-10-01
JP2020528758A5 true JP2020528758A5 (enExample) 2021-09-09
JP7297734B2 JP7297734B2 (ja) 2023-06-26

Family

ID=59626578

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505231A Active JP7297734B2 (ja) 2017-07-31 2018-07-30 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体
JP2023097920A Withdrawn JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023097920A Withdrawn JP2023123588A (ja) 2017-07-31 2023-06-14 可変ドメインと定常ドメインとの間のエルボー領域に機能的ドメインを有する抗体

Country Status (13)

Country Link
US (1) US12331108B2 (enExample)
EP (1) EP3661962A1 (enExample)
JP (2) JP7297734B2 (enExample)
KR (1) KR20200032738A (enExample)
CN (1) CN111094341A (enExample)
AU (1) AU2018311032B2 (enExample)
BR (1) BR112019028180A2 (enExample)
CA (1) CA3069265A1 (enExample)
EA (1) EA202090364A1 (enExample)
IL (1) IL272303A (enExample)
MX (1) MX2020001080A (enExample)
SG (1) SG11201911658QA (enExample)
WO (2) WO2019024979A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
BR112020018918A2 (pt) 2018-03-22 2021-01-05 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
MX2020012895A (es) 2018-05-30 2021-05-27 Inst Res Biomedicine Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena.
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
EP4100434A1 (en) 2020-02-03 2022-12-14 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
TWI859420B (zh) 2020-02-26 2024-10-21 美商維爾生物科技股份有限公司 抗sars-cov-2抗體及使用其之方法
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
EP4135846A1 (en) 2020-04-14 2023-02-22 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023525039A (ja) 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Sars-cov-2に対する抗体
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3180477A1 (en) 2020-06-12 2021-12-16 Elizabeth Alexander Antibody therapies for sars-cov-2 infection
EP4217385A2 (en) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antibodies against sars-cov-2
CN112225807B (zh) * 2020-10-30 2021-09-07 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
JP2023551667A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド 抗-インフルエンザ抗体及びその組合せ
KR20230135569A (ko) 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
WO2022109309A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Broadly neutralizing antibodies against influenza neuraminidase
WO2022115486A1 (en) 2020-11-25 2022-06-02 Vir Biotechnology, Inc. Antibodies that bind to multiple betacoronaviruses
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4271715A4 (en) * 2020-12-30 2024-11-20 Wuxi Biologics Ireland Limited MULTI-SPECIFIC ANTIGEN-BINDING PROTEINS
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2022236142A2 (en) * 2021-05-07 2022-11-10 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
AU2022280767A1 (en) 2021-05-24 2024-01-18 Humabs Biomed Sa Engineered polypeptides
WO2023034866A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用
EP4444758A2 (en) 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20230416406A1 (en) 2022-03-10 2023-12-28 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
JP2025522295A (ja) 2022-05-23 2025-07-15 ヒューマブス・バイオメッド・ソシエテ・アノニム インフルエンザノイラミニダーゼに対する広域中和抗体
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
EP4562034A1 (en) 2022-07-27 2025-06-04 Humabs Biomed SA Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2024215762A1 (en) 2023-04-10 2024-10-17 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en) 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
EP2626371A1 (en) * 2007-07-31 2013-08-14 MedImmune, LLC Multispecific epitope binding proteins and uses thereof
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20140235476A1 (en) * 2012-12-28 2014-08-21 Abbvie, Inc. Multivalent binding protein compositions and methods for identifying variants of same
HK1216894A1 (zh) * 2012-12-28 2016-12-09 Abbvie Inc. 多價結合蛋白組合物
US9814784B2 (en) 2013-01-03 2017-11-14 Celltrion, Inc. Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
US10526404B2 (en) * 2015-04-29 2020-01-07 Institute For Research In Biomedicine Multispecific anti GM-CSF antibodies
AU2016277887B2 (en) * 2015-06-18 2022-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulin single variable domain antibody against RSV prefusion F protein
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
EP3313871A1 (en) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
KR20180085800A (ko) * 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides

Similar Documents

Publication Publication Date Title
JP2020528758A5 (enExample)
Chmielewski et al. TRUCKs: the fourth generation of CARs
CN113260368B (zh) 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途
JP2019502379A5 (enExample)
JP6449143B2 (ja) 二重特異性を有する融合タンパク質産生のための共有結合したホモ二量体化モジュールとしてのIgMおよびIgE重鎖ドメイン2
AU2023201197A1 (en) Chimeric transmembrane proteins and uses thereof
Geering et al. Synthetic immunology: modulating the human immune system
JP2019088330A5 (enExample)
JP2018514199A5 (enExample)
RU2009100153A (ru) Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
JP2015511219A (ja) 標的変異体αヘリックスバンドルサイトカイン
RU2749113C2 (ru) Содержащая рнк композиция для лечения опухолевых заболеваний
JP2019508017A5 (enExample)
TWI811212B (zh) 嵌合多肽及改變其膜定位之方法
Aung et al. Recent and future perspectives on engineering interferons and other cytokines as therapeutics
AU2018277294A1 (en) Oncolytic virus and method
EP3768700A1 (en) Chimeric transmembrane proteins and uses thereof
WO2019126358A1 (en) Single- and multi-chain chimeric antigen receptors
JP2018521959A5 (enExample)
TW202144396A (zh) 抑制性嵌合受體架構
CN114805573B (zh) 抗tim3单克隆抗体和嵌合抗原受体
Shen et al. 4-1BB targeting immunotherapy: mechanism, antibodies, and chimeric antigen receptor T
EP4100027A1 (en) Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
US20250297276A1 (en) Macrophage-specific promoters and uses thereof
WO2021204204A1 (zh) 一种转染抗原基因的细胞疫苗及相关免疫细胞